Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies

Mullins, Stefanie; P. Vasilakos, John; Deschler, Katharina; F. Grigsby, Iwen; Gillis, Pete; Paul Pradeep John, Julius; J. Elder, Matthew; G. Swales, John; Timosenko, Elina; A. Cooper, Zachary; J. Dovedi, Simon; J. Leishman, Andrew; Luheshi, Nadia; Elvecrog, James; Y. Tilahun, Ashenafi; J. A. Goodwin, Richard; Herbst, Ronald; A. Tomai, Mark; W. Wilkinson, Robert

doi:10.1186/s40425-019-0724-8

Public

Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies

Published in Journal for ImmunoTherapy of Cancer • Sep 11, 2019

Authors:

Stefanie Mullins

John P. Vasilakos

Katharina Deschler

Abstract

Background Immune checkpoint blockade (ICB) promotes adaptive immunity and tumor regression in some cancer patients. However, in patients with immunologically “cold” tumors, tumor-resident innate immune cell activation may be required to prime an adaptive immune response and so exploit the full pote...

Subject

TLR7

Agonist

Immune system

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!